REG - Venture Life Group - Grant of Share Options

Venture LifeAnnouncement

25/07/2025 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250725:nRSY5153Sa&default-theme=true

RNS Number : 5153S  Venture Life Group PLC  25 July 2025

25 July 2025

 

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Grant of Share Options

 

 

Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, announces
that, pursuant to the Company's 2023 Long Term Incentive Plan ("LTIP"), it has
granted options to subscribe for an aggregate of 2,500,000 ordinary shares of
0.3p each in the capital of the Company (the "Options") to the Company's
Directors, as follows:

 

 Director       Number of Options Granted  Exercise Price
 Jerry Randall  1,000,000                  57.70 pence
 Daniel Wells   1,000,000                  57.70 pence
 Paul McGreevy  500,000                    57.70 pence

 

The Options (which are subject to malus and clawback provisions) will vest
after three years following publication of the Company's annual results for
2027 and will be exercisable within 7 years of vesting. Vesting is conditional
on the achievement of certain performance criteria which include a total
shareholder return and earnings per share measurement.

 

 

Further detail is provided below in accordance with Article 19.3 of the EU
Market Abuse Regulation.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Jerry Randall

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Grant of share options

 c)   Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            57.70p    1,000,000

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      25 July 2025

 f)   Place of the transaction                                     London Stock Exchange

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

n/a

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

25 July 2025

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Daniel Wells

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Grant of share options

 c)   Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            57.70p    1,000,000

 

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      25 July 2024

 f)   Place of the transaction                                     London Stock Exchange

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

n/a

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

25 July 2024

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Paul McGreevy

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chair

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Grant of share options

 c)   Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            57.70p    500,000

 

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      25 July 2024

 f)   Place of the transaction                                     London Stock Exchange

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

n/a

 

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

25 July 2024

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

 

 

For further information, please contact:

 

Venture Life Group
PLC
                +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

 

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHRIMLTMTBTBJA